{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:09:14Z","timestamp":1773292154434,"version":"3.50.1"},"reference-count":43,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1932,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1111\/j.1478-3231.2010.02265.x","type":"journal-article","created":{"date-parts":[[2010,5,24]],"date-time":"2010-05-24T15:36:39Z","timestamp":1274715399000},"page":"1049-1058","source":"Crossref","is-referenced-by-count":14,"title":["Non-invasive assessment of liver fibrosis progression in hepatitis C patients retreated for 96 weeks with antiviral therapy: a randomized study"],"prefix":"10.1111","volume":"30","author":[{"given":"Jean-Pierre","family":"Zarski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Sturm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herv\u00e9","family":"Desmorat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Melin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Jacques","family":"Raabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Bonny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Sogni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandrina","family":"Pinta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie","family":"Rouanet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e9rard","family":"Babany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Cheveau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mich\u00e8le","family":"Chevallier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,5,18]]},"reference":[{"key":"10.1111\/j.1478-3231.2010.02265.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1056\/NEJM199506013322202","article-title":"Clinical outcomes after transfusion-associated hepatitis C","volume":"332","author":"Tong","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1478-3231.2010.02265.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1002\/hep.1840360706","article-title":"Natural history of chronic hepatitis C","volume":"36","author":"Seeff","year":"2002","journal-title":"Hepatology"},{"key":"10.1111\/j.1478-3231.2010.02265.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1478-3231.2010.02265.x-BIB4|cit4","first-page":"958","article-title":"Peg-Interferon alfa-2b plus ribavirin compared with interferon alfa 2-b plus ribavirin for initial treatment of chronic hepatitis C","volume":"358","author":"Manns","year":"2001","journal-title":"a randomized trial"},{"key":"10.1111\/j.1478-3231.2010.02265.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1053\/jhep.2000.19347","article-title":"Impact of interferon alfa-2b and ribavirin on the progression of liver fibrosis in patients with chronic hepatitis C","volume":"32","author":"Poynard","year":"2000","journal-title":"Hepatology"},{"key":"10.1111\/j.1478-3231.2010.02265.x-BIB6|cit6","first-page":"47","article-title":"Fibrosis in patients with chronic hepatitis C","volume":"20","author":"Poynard","year":"2000","journal-title":"detection and significance"},{"key":"10.1111\/j.1478-3231.2010.02265.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0140-6736(00)03595-9","article-title":"Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis","volume":"357","author":"Nishiguchi","year":"2001","journal-title":"Lancet"},{"key":"10.1111\/j.1478-3231.2010.02265.x-BIB8|cit8","first-page":"689","article-title":"Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis","volume":"15","author":"Papatheodoridis","year":"2001","journal-title":"a meta-analysis"},{"key":"10.1111\/j.1478-3231.2010.02265.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/hep.510260335","article-title":"Relationship between biochemical, virological and histological response during interferon treatment of chronic hepatitis C","volume":"26","author":"Shiffman","year":"1997","journal-title":"Hepatology"},{"key":"10.1111\/j.1478-3231.2010.02265.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/0016-5085(90)90627-D","article-title":"Oxidant injury to hepatic mitochondrial lipids in rats with dietary copper overload","volume":"99","author":"Sokol","year":"1990","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1478-3231.2010.02265.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11894-005-0066-1","article-title":"Maintenance therapy for chronic hepatitis C","volume":"7","author":"Kelleher","year":"2005","journal-title":"Current Gastroenterol Rep"},{"key":"10.1111\/j.1478-3231.2010.02265.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMoa0707615","article-title":"Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon","volume":"359","author":"Di Bisceglie","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1478-3231.2010.02265.x-BIB13|cit13","first-page":"618","article-title":"Liver fibrogenesis and the role of hepatic stellate cells","volume":"14","author":"Li","year":"1999","journal-title":"new insights and prospects for therapy"},{"key":"10.1111\/j.1478-3231.2010.02265.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/hep.510270512","article-title":"Effect of antioxidants, resveratrol, quercetin, and N-acetylcysteine, on the functions of cultured rat hepatic stellate cells and Kuppfer cells","volume":"27","author":"Kawada","year":"1998","journal-title":"Hepatology"},{"key":"10.1111\/j.1478-3231.2010.02265.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1053\/gast.1997.v113.pm9322499","article-title":"A pilot study of the effects of alfa-tocopherol on hepatic stellate cell activation in chronic hepatitis C","volume":"113","author":"Houglum","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1478-3231.2010.02265.x-BIB16|cit16","first-page":"886","article-title":"Progression of fibrosis in advanced chronic hepatitis C","volume":"45","author":"Goodman","year":"2007","journal-title":"evaluation by morphometric image analysis"},{"key":"10.1111\/j.1478-3231.2010.02265.x-BIB17|cit17","first-page":"1028","article-title":"Long-term evolution of fibrosis from chronic hepatitis to cirrhosis in patients with hepatitic C","volume":"25","author":"Kage","year":"1997","journal-title":"morphometric analysis of repeated biopsies"},{"key":"10.1111\/j.1478-3231.2010.02265.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/j.1478-3231.2005.01155.x","article-title":"Advances in digital quantification technique enhance discrimination between mild and advanced liver fibrosis in chronic hepatitis C","volume":"25","author":"Lazzarini","year":"2005","journal-title":"Liver Int"},{"key":"10.1111\/j.1478-3231.2010.02265.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1309\/D7AU-EYW7-4B6C-K08Y","article-title":"An assessment of digital image analysis to measure fibrosis in liver biopsy specimens of patients with chronic hepatitis C","volume":"114","author":"O'Brien","year":"2000","journal-title":"Am J Clin Pathol"},{"key":"10.1111\/j.1478-3231.2010.02265.x-BIB20|cit20","first-page":"439","article-title":"Histological evaluation of liver fibrosis","volume":"28","author":"Pilette","year":"1998","journal-title":"quantitative image analysis vs semi-quantitative scores. Comparison with serum markers"},{"key":"10.1111\/j.1478-3231.2010.02265.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/S0168-8278(01)00006-X","article-title":"Liver fibrosis assessment with semiquantitative indexes and image analysis quantification in sustained-responder and non-responder interferon-treated patients with chronic hepatitis","volume":"34","author":"Caballero","year":"2001","journal-title":"C. J Hepatol"},{"key":"10.1111\/j.1478-3231.2010.02265.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/hep.1840200104","article-title":"Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR cooperative study group","volume":"20","year":"1994","journal-title":"Hepatology"},{"key":"10.1111\/j.1478-3231.2010.02265.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.510240201","article-title":"An algorithm for the grading of activity in chronic hepatitis C. The METAVIR cooperative study group","volume":"24","author":"Bedossa","year":"1996","journal-title":"Hepatology"},{"key":"10.1111\/j.1478-3231.2010.02265.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","article-title":"Histological grading and staging of chronic hepatitis","volume":"22","author":"Ishak","year":"1995","journal-title":"J Hepatol"},{"key":"10.1111\/j.1478-3231.2010.02265.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1471-230X-7-40","article-title":"Meta-analyses of FibroTest diagnostic value in chronic liver disease","volume":"7","author":"Poynard","year":"2007","journal-title":"BMC Gastroenterol"},{"key":"10.1111\/j.1478-3231.2010.02265.x-BIB26|cit26","first-page":"1738","article-title":"Fibrosis progression in chronic hepatitis C","volume":"50","author":"Goodman","year":"2009","journal-title":"morphometric image analysis in the HALT-C trial"},{"key":"10.1111\/j.1478-3231.2010.02265.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1053\/j.gastro.2009.08.067","article-title":"Effect of HCV RNA suppression during Peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C Trial","volume":"137","author":"Shiffman","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1478-3231.2010.02265.x-BIB28|cit28","first-page":"G116","article-title":"Effect of vitamin E supplementation on hepatic fibrogenesis in chronic dietary iron overload","volume":"272","author":"Brown","year":"1997","journal-title":"Am J Physiol"},{"key":"10.1111\/j.1478-3231.2010.02265.x-BIB29|cit29","first-page":"599","article-title":"Vitamin E improves the aminotransferase status of patients suffering from viral hepatitis C","volume":"27","author":"Von Herbay","year":"1997","journal-title":"a randomized, double-blind, placebo-controlled study"},{"key":"10.1111\/j.1478-3231.2010.02265.x-BIB30|cit30","first-page":"1029A","article-title":"The one-year antifibrotic pentoxyphillin\/alpha-tocopherol association does not limit liver firosis progression in patients with chronic hepatitis C - ANRS HC 10","volume":"50","author":"Fontaine","year":"2009","journal-title":"Hepatology"},{"key":"10.1111\/j.1478-3231.2010.02265.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJM200012073432302","article-title":"Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis","volume":"343","author":"Heathcote","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1478-3231.2010.02265.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1053\/jhep.2001.21747","article-title":"Efficacy and safety of pegylated (40-kd) interferon \u03b1-2a compared with interferon \u03b1-2a in in non cirrhotic patients with chronic hepatitis C","volume":"33","author":"Reddy","year":"2001","journal-title":"Hepatology"},{"key":"10.1111\/j.1478-3231.2010.02265.x-BIB33|cit33","first-page":"125","article-title":"Long-term administration of interferon-\u03b1 in non responder patients with chronic hepatitis C","volume":"6","author":"Guerret","year":"1999","journal-title":"follow-up of liver fibrosis over 5 years"},{"key":"10.1111\/j.1478-3231.2010.02265.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/hep.1840180610","article-title":"Interferon-alpha 2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis; a quantitative histological evaluation","volume":"18","author":"Manabe","year":"1993","journal-title":"Hepatology"},{"key":"10.1111\/j.1478-3231.2010.02265.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.hep.2003.09.022","article-title":"Sampling variability of liver fibrosis in chronic hepatitis C","volume":"38","author":"Bedossa","year":"2003","journal-title":"Hepatology"},{"key":"10.1111\/j.1478-3231.2010.02265.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/hep.20535","article-title":"Sources of variability in histological scoring of chronic viral hepatitis","volume":"41","author":"Rousselet","year":"2005","journal-title":"Hepatology"},{"issue":"(S","key":"10.1111\/j.1478-3231.2010.02265.x-BIB37|cit37","first-page":"19","article-title":"Assessment of hepatitis C","volume":"29","author":"Bedossa","year":"2009","journal-title":"non-invasive fibrosis markers and\/or liver biopsy"},{"key":"10.1111\/j.1478-3231.2010.02265.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1365-2893.2008.01062.x","article-title":"An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C","volume":"16","author":"Patel","year":"2009","journal-title":"J Viral Hepat"},{"key":"10.1111\/j.1478-3231.2010.02265.x-BIB39|cit39","first-page":"128","article-title":"Biochemical markers of liver fibrosis in patients infected by hepatitis C virus","volume":"9","author":"Poynard","year":"2002","journal-title":"longitudinal validation in a randomized trial"},{"key":"10.1111\/j.1478-3231.2010.02265.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/j.1478-3231.2008.01789.x","article-title":"Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C","volume":"28","author":"Cal\u00e8s","year":"2008","journal-title":"Liver Int"},{"key":"10.1111\/j.1478-3231.2010.02265.x-BIB41|cit41","first-page":"529","article-title":"Evolving pratices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France","volume":"46","author":"Cast\u00e9ra","year":"2007","journal-title":"time for new guidelines?"},{"issue":"(S","key":"10.1111\/j.1478-3231.2010.02265.x-BIB42|cit42","first-page":"S312","article-title":"Liver fibrosis assessment in chronic hepatitis C","volume":"48","author":"Roudot-Thoraval","year":"2008","journal-title":"evolution of clinical practice in a large cohort of 4546 patients between 2003 and 2006"},{"key":"10.1111\/j.1478-3231.2010.02265.x-BIB43|cit43","first-page":"S4","article-title":"Colchicine versus Peg-Interferon alfa-2b long term therapy","volume":"48","author":"Afdhal","year":"2008","journal-title":"results of the 4 year COPILOT trial"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1478-3231.2010.02265.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1478-3231.2010.02265.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T02:51:12Z","timestamp":1740106272000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1478-3231.2010.02265.x"}},"subtitle":["Non-invasive assessment of liver fibrosis progression"],"short-title":[],"issued":{"date-parts":[[2010,5,18]]},"references-count":43,"journal-issue":{"issue":"7"},"URL":"https:\/\/doi.org\/10.1111\/j.1478-3231.2010.02265.x","relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,18]]}}}